Executive Officers

Sandeep Wasan, 39
Chief Executive Officer and Director

Mr. Wasan is a Managing Director in Financial Advisory at Lazard, where he primarily focuses on clients and transactions in the healthcare sector. Mr. Wasan has advised on a multitude of mergers, acquisitions, divestitures, leverage buyouts, IPOs and other capital markets transactions over the course of his career. Prior to joining Lazard in 2014, Mr. Wasan worked in the healthcare groups at Sagent Advisors and UBS Investment Bank. Mr. Wasan also previously worked at Bristol-Myers Squibb and General Catalyst and has served in the Singapore Air Force. Mr. Wasan has a B.S. in Management Science & Engineering from Stanford University and an M.B.A. in Finance and Healthcare Management from Columbia Business School.

Mary Ann Deignan, 59
Chief Financial Officer and Director

Ms. Deignan is a Managing Director and Co-Head of Capital Markets Advisory at Lazard, advising clients on shareholder activism, strategic investor relations, capital raising and corporate governance. Ms. Deignan also serves as the Chief Financial Officer, and a Director of LGAC I and of LHCA I, special purpose acquisition companies sponsored by indirect subsidiaries of Lazard Ltd (and therefore affiliates of our sponsor). Ms. Deignan joined Lazard from Bank of America Merrill Lynch, where she was Co-Head of Global Equity Capital Markets, a role she assumed after her tenure as Head of Americas Equity Capital Markets. She also worked for UBS as Head of Americas Equity Capital Markets. Ms. Deignan began her career at Bankers Trust in leveraged finance. Ms. Deignan provides expert guidance across regions and market sectors on a range of shareholder and corporate finance matters including activism preparedness and defense, investor perspectives on M&A and strategic actions, IPO advisory and capital raising, trends in ESG and corporate governance. Ms. Deignan has extensive knowledge of the global equity markets and public market investors. Ms. Deignan is on the Investment Committee of the Margaret A. Cargill Philanthropies and the Board of Advisors at the Hospital for Special Surgery in NYC. She has a B.A. from Mount Holyoke College and an M.B.A. from the Tuck School at Dartmouth.

Board of Directors

Alexander Stern, 55
Executive Chairman and Director

Mr. Stern has served as President of Lazard Ltd and Lazard Group since June 2019 and as a Managing Director of Lazard since 2002. Mr. Stern has previously served in various other leadership capacities at Lazard, including Chief Executive Officer of Lazard’s financial advisory business, Chief Operating Officer of Lazard and Global Head of Strategy of Lazard. Mr. Stern also serves as the Executive Chairman and a Director of LGAC I and of LHCA I, special purpose acquisition companies sponsored by indirect subsidiaries of Lazard Ltd (and therefore affiliates of our sponsor). Mr. Stern is recognized as a proven financial advisor in the technology sector with a track record of leading complex transformational growth and value creation initiatives for clients. Prior to joining Lazard, Mr. Stern held various positions with Patricof & Co. Ventures and IBM. Mr. Stern is Chairman of the LUNGevity Foundation and a member of the Board of Advisors for the School of Engineering and Applied Sciences of the University of Pennsylvania. Mr. Stern earned a B.S. from Duke University, an M.S.E. from the School of Engineering and Applied Science at the University of Pennsylvania and an M.B.A. from the University of Pennsylvania, Wharton School.

Richard Maroun, 66
Director Nominee

Mr. Maroun has held management and executive leadership positions in pharmaceutical and life science companies for more than 20 years and is currently a Partner and General Counsel of Frazier Healthcare Partners, a position he has held since June 2014. From 2012 through February 2014, Mr. Maroun was the Senior Vice President, General Counsel and Corporate Secretary of Aptalis Pharma US, Inc. From 2007 to 2011, Mr. Maroun served as the Executive Vice President, Chief Administrative Officer, General Counsel, Business Development Officer and Corporate Secretary of APP Pharmaceuticals, Inc. From 2006 to 2007, Mr. Maroun was the Executive Vice President, Chief Administrative Officer, General Counsel and Corporate Secretary of Abraxis BioScience, Inc. From 2004 to 2006, Mr. Maroun was Vice President, Business Development and General Counsel of American BioScience, Inc. Prior to joining American BioScience, Mr. Maroun was a Director of Merrill Lynch, Pierce, Fenner & Smith, and before that he was a Senior Tax Manager of Deloitte & Touche. Mr. Maroun received his B.S. degree in Economics from John Carroll University in 1977, his J.D. Degree from Santa Clara University in 1979 and his L.L.M. in Taxation from Boston University Law School in 1981. Mr. Maroun served as a director of Organovo Holdings, Inc. until 2020 and is currently a director of Aadi Bioscience, Inc. as well as a board member or advisor of several privately-held companies funded by Frazier Healthcare Partners, including Community Care Health Network, LLC, Parata Systems, Inc., Orthotic Holdings, Inc., and AppianRx.

Noreen Roth Henig, 56
Director Nominee

Dr. Henig is the Chief Medical Officer of Kezar Life Sciences, Inc., a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. Dr. Henig also serves as a Director of LGAC I, a special purpose acquisition company sponsored by an indirect subsidiary of Lazard Ltd (and therefore affiliate of our sponsor). Prior to Kezar Life Sciences, Inc., Dr. Henig served as Chief Medical Officer of Breath Therapeutics Holdings BV, a biotechnology company developing a first-in-class inhaled drug-device therapy that was recently acquired by Zambon SpA. Prior to joining Breath Therapeutics Holding BV, she was Chief Medical Officer at ProQR Therapeutics N.V., a private company that completed an initial public offering as a preclinical phase biotechnology company. Since 2019, Dr. Henig has also served on the board of directors of Avidity Biosciences, which recently completed its initial public offering as a preclinical company in June 2020. Dr. Henig holds a B.A. in History of Art from Yale University and an M.D. with distinction in Immunology from Albert Einstein College of Medicine of Yeshiva University.

Selina Tobaccowala, 44
Director Nominee

Ms. Tobaccowala also serves as a Director of LGAC I, a special purpose acquisition company sponsored by an indirect subsidiary of Lazard Ltd (and therefore affiliate of our sponsor). Ms. Tobaccowala is currently the Chief Digital Officer at Openfit, a digital streaming platform that integrates fitness, nutrition and wellness and provides fitness programs with live trainer-led and on-demand workouts. From April 2016 to August 2019, Ms. Tobaccowala was the Chief Executive Officer of Gixo, an innovative live workout fitness start-up aimed at improving global health and activity rates, which she also co-founded and which was acquired by Openfit in 2019. Prior to that, she served as the President and Chief Technology Officer at SurveyMonkey, an online survey development company, from October 2009 to April 2016, Senior Vice President of Product & Technology of Ticketmaster Europe from March 2005 to October 2009 and Vice President of Engineering for Evite.com, which she co-founded, from April 1997 to April 2001. Ms. Tobaccowala has a bachelor’s degree from Stanford University. Ms. Tobaccowala has served on the board of directors of Redfin since 2014 and as an advisory board member of HubSpot since 2015.

Carl Goldfischer, 63
Director Nominee

Dr. Goldfischer currently serves as an advisor to Bay City Capital having previously served as a Managing Director since 2000. His investment and capital market expertise spans all subsectors within life sciences in both private and public companies. He has been a founding investor and served as a director of numerous companies including MAP Pharmaceuticals and Oculex (both sold to Allergan), Nevro, Pharmakea and Ora Clinical Research. He is also the founder and Executive Chairman of Bridge Medicines, a New York City-based company focused on developing novel therapeutics in partnership with three leading academic, medical and research institutions: Rockefeller University, Weill Cornell Medical Center and Memorial Sloan Kettering Cancer Center. Dr. Goldfischer currently serves as a director and is chairman of the audit committee for three publicly traded companies: Epizyme, Imara and Galecto. Dr. Goldfischer received an M.D. with honors in Scientific Research from Albert Einstein College of Medicine and a B.A. from Sarah Lawrence College.